	US 12,433,948 B2
	Aqueous pharmaceutical formulations
Jheng-Gang Yang, Taiwan (CN); Wen-Cheng Chang, Taiwan (CN); and Jiung-Liang Liu, Taiwan (CN)
Assigned to RICHTER GEDEON NYRT, Budapest (HU)
Appl. No. 17/290,092
Filed by RICHTER GEDEON NYRT, Budapest (HU)
PCT Filed Oct. 24, 2019, PCT No. PCT/CN2019/113112 § 371(c)(1), (2) Date Apr. 29, 2021, PCT Pub. No. WO2020/088346, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/753,084, filed on Oct. 31, 2018.
Prior Publication US 2021/0393783 A1, Dec. 23, 2021
Int. Cl. A61K 47/18 (2017.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); C07K 16/28 (2006.01)

CPC A61K 47/183 (2013.01) [A61K 9/0019 (2013.01); A61K 47/26 (2013.01); C07K 16/2866 (2013.01)]

12 Claims

1. An aqueous pharmaceutical formulation comprising,

an antibody that binds to the receptor of (IL)-6;

histidine at a concentration of 60 mM to 150 mM; and

a surfactant at a concentration of 0.01-0.05% (w/v);

wherein the antibody is the anti-IL-6R antibody tocilizumab and is present in the aqueous pharmaceutical formulation at a concentration of 180 mg/mL; and

wherein the aqueous pharmaceutical formulation has a pH of 5.0-6.5.